• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dermata Therapeutics Inc.

    8/7/24 4:49:30 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRMA alert in real time by email
    S-8 1 drma_s8.htm FORM S-8 drma_s8.htm

    As filed with the Securities and Exchange Commission on August 7, 2024

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 

    ____________________________________________________

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

    ____________________________________________________

     

    DERMATA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    86-3218736

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

    3525 Del Mar Heights Rd., #322

    San Diego, CA

     

     

    92130

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

    Gerald T. Proehl

    Chief Executive Officer

    3525 Del Mar Heights Rd., #322

    San Diego, CA 92130

    (Name and address of agent for service)

     

    Tel: (858) 800-2543

    (Telephone number, including area code, of agent for service)

    ____________________________________________________

     

    Please send copies of all communications to:

    Steven M. Skolnick, Esq.

    Michael J. Lerner, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 262-6700

    ____________________________________________________

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed by Dermata Therapeutics, Inc. (the “Company”) for the purpose of registering an additional aggregate 40,612 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) under the Company’s 2021 Omnibus Equity Incentive Plan (as amended, the “2021 Plan”) consisting of (i) 2,620 shares of Common Stock (“Evergreen Shares”) available for grant and issuance under the 2021 Plan as of January 1, 2024 pursuant to an automatic annual increase on January 1 of each year beginning in 2022 by an amount equal to 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year (the “Evergreen Provision”) and (ii) 37,992 shares of Common Stock pursuant to an amendment to the 2021 Plan approved by the Company’s stockholders on May 7, 2024 (the “Amendment Shares”).

     

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statement on Form S-8 of the Company filed with the Securities and Exchange Commission (the “SEC”) on December 10, 2021, (Registration No. 333-261606), August 26, 2022, (Registration No. 333-267115) and September 14, 2023 (Registration No. 333-274513) (collectively, the “Prior Form S-8s”) including any amendments thereto or filings incorporated therein, are incorporated herein by this reference to the extent not replaced hereby. The shares of Common Stock registered pursuant to this Registration Statement are of the same class of securities as the 79,930 shares of Common Stock registered for issuance under the 2021 Plan pursuant to the Prior Form S-8s.

     

     
    2

     

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Company with the SEC pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

     

    (a)

    the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 21, 2024;

     

     

     

     

    (b)

    portions of our definitive proxy statement on Schedule 14A incorporated by reference to our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 26, 2024;

     

     

     

     

    (c)

    the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, as filed with the SEC on May 15, 2024 and August 7, 2024;

     

     

     

     

    (d)

    the Company’s Current Reports on Form 8-K as filed with the SEC on January 12, 2024, May 7, 2024, May 14, 2024, May 15, 2024, May 17, 2024, May 24, 2024, June 5, 2024, June 7, 2024, and August 2, 2024 (other than any portions thereof deemed furnished and not filed); and

     

     

     

     

    (e)

    the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on August 11, 2021, including any amendments and reports filed for the purpose of updating such description, including the description of our common stock included as Exhibit 4.12 to our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 21, 2024.

     

    All documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein; provided, however, that documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

     
    3

     

     

    Item 8. Exhibits.

     

    Exhibit

    Number

     

     

    Description of Document

    4.1

     

    Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 of the Company’s Registration Statement on Form S-1 filed with the SEC on August 6, 2021).

    4.2

     

    Amendment No. 1 of the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on July 11, 2022 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 11, 2022).

    4.3

     

    Amendment No. 2 of the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., filed with Secretary of State of Delaware on March 13, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 13, 2023).

    4.4

     

    Amendment No. 3 to the Amended and Restated Certificate of Incorporation of Dermata Therapeutics, Inc., filed with the Secretary of State of Delaware on May 14, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 14, 2024).

    4.5

     

    Amended and Restated Bylaws of Dermata Therapeutics, Inc. (incorporated by reference to Exhibit 3.4 of the Company’s Registration Statement on Form S-1 filed with the SEC on August 6, 2021).

    4.6

     

    Amendment No. 1 to the Amended and Restated Bylaws of Dermata Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 23, 2022).

    4.7

     

    Specimen Certificate representing shares of common stock of Dermata Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the SEC on August 6, 2021).

    4.8

     

    Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 on Form S-1 filed with the SEC on June 10, 2021).

    4.9

     

    Amendment No. 1 to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.14 on Form S-1/A filed with the SEC on July 2, 2021).

    4.10

     

    Amendment No. 2 to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on Form 8-K filed with SEC on August 3, 2023).

    4.11

     

    Amendment No. 3 to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on Form 8-K filed with SEC on May 7, 2024).

    4.12

     

    Form of Nonqualified Stock Option Award (incorporated by reference to Exhibit 10.3 on Form S-1 filed with the SEC on June 10, 2021).

    4.13

     

    Form of Incentive Stock Option Award (incorporated by reference to Exhibit 10.4 on Form S-1 filed with the SEC on June 10, 2021).

    5.1

     

    Legal opinion of Lowenstein Sandler LLP*

    23.1

     

    Consent of Moss Adams LLP, Independent Registered Public Accounting Firm *

    23.2

     

    Consent of Mayer Hoffman McCann P.C., Independent Registered Public Accounting Firm *

    23.3

     

    Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1)

    24.1

     

    Power of Attorney (contained on the signature page of this registration statement on Form S-8)

    107.1

     

    Filing Fee Table

     

    * Filed herewith.

     

     
    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on August 7, 2024.

     

    DERMATA THERAPEUTICS, INC.

     

     

     

     

     

     

    By:

    /s/ Gerald T. Proehl

     

     

     

    Gerald T. Proehl

     

     

     

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gerald T. Proehl and Kyri K. Van Hoose, and each of them, each with full power to act without the other, his true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any amendments to this registration statement, and to sign any registration statement for the same offering covered by this registration statement, including post-effective amendments or registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming that each of said such attorneys-in-fact and agents or his substitute or substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Company in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

     

     

     

     

    /s/ Gerald T. Proehl

     

    President, Chief Executive Officer and Chairman

    (Principal Executive Officer) 

     

    August 7, 2024

    Gerald T. Proehl

     

     

     

     

     

     

     

     

    /s/ Kyri K. Van Hoose

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer) 

     

    August 7, 2024

    Kyri K. Van Hoose

     

     

     

     

     

     

     

     

    /s/ David Hale

     

    Lead Director

     

    August 7, 2024

    David Hale

     

     

     

     

     

     

     

     

    /s/ Wendell Wierenga

     

    Director

     

    August 7, 2024

    Wendell Wierenga, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Mary Fisher

     

    Director

     

    August 7, 2024

    Mary Fisher

     

     

     

     

     

     

     

     

    /s/ Andrew Sandler

     

    Director

     

    August 7, 2024

    Andrew Sandler, M.D.

     

     

     

     

     

     

     

     

    /s/ Steven J. Mento

     

    Director

     

    August 7, 2024

    Steven J. Mento, Ph.D.

     

     

     

     

     

     

     

     

    /s/ Kathleen Scott

     

    Director

     

    August 7, 2024

    Kathleen Scott

     

     

     

     

     

     

     

     

    /s/ Brittany Bradrick

     

    Director

     

    August 7, 2024

    Brittany Bradrick

     

     

     

     

     
    5

     

    Get the next $DRMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRMA

    DatePrice TargetRatingAnalyst
    9/21/2021$14.00Buy
    Brookline Capital
    9/14/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sandler Andrew Seth

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:08 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wierenga Wendell

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:11 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Senior VP, CDO Nardo Christopher J.

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:08 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/9/26 5:45:18 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/3/26 4:05:34 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/2/26 6:35:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Life Science Virtual Investor Forum Agenda Announced for September 18th

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please schedule 1x1 meetings here "We are excited to highlight today's innovators from the life scienc

    9/16/25 11:57:15 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

    SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com San Diego, CA, September 16, 2025 -- Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW)) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Gerry Proehl, Founder and CEO of Dermata, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025. DATE: September 18th TIME: 11:30 AM ESTLINK: REGISTER HERE

    9/16/25 8:35:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Dermata Therapeutics with a new price target

    Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00

    9/21/21 10:38:17 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Dermata Therapeutics with a new price target

    Maxim Group initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $9.00

    9/14/21 10:01:43 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee."I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive Officer, President, and Chairman. "Brittany brings an immense amount of industry expertise to Dermata and has an accomplished background with over 25 years' experience in finance, strategy, and corporate development for life science companies, with both opera

    1/13/22 8:30:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer

    SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced the appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer. Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience, including more than 15 years in the life sciences industry. Ms. Van Hoose is replacing Thomas Insley, who is retiring as the Company's full time CFO after 6 years, but will continue to work with the Company as a financial consultant."I am very excited to welcome Kyri

    9/1/21 6:00:00 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dermata Therapeutics Inc.

    SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/14/24 3:35:03 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dermata Therapeutics Inc.

    SC 13G - Dermata Therapeutics, Inc. (0001853816) (Subject)

    6/1/23 5:23:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    Financials

    Live finance-specific insights

    View All

    Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

    - End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410 partnering discussions ongoing -SAN DIEGO, CA / ACCESSWIRE / February 21, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the year ended December 31, 2022."We are very excited for what Dermata has planned for 2023 for both our DMT310 and DMT410 programs," sai

    2/21/23 4:05:00 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

    - DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 -- Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 -SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW))) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress, and reported financial results for the quarter ended September 30, 2022."I am thrilled with all that Dermata has accomplished so far this year and plan to continue the momentum as we near the announcement of our DMT310 Phase 2 topline result

    11/10/22 5:20:00 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care